ROCHESTER, Minn. — A Mayo Clinic researcher, along with his collaborators, has shown that an individual's genomic makeup and diet interact to determine which microbes exist and how they act in the host intestine. The study was modeled in germ-free knockout mice to mimic a genetic condition that affects 1 in 5 humans and increases the risk for digestive diseases. The findings appear in theProceedings of the National Academy of Sciences.
"Our data show that factors in the differences in a host's genetic makeup — in this case genes that affect carbohydrates in the gut — interact with the type of food eaten. That combination determines the composition and function of resident microbes," says Purna Kashyap, M.B.B.S., a Mayo Clinic gastroenterologist and first author of the study. He is also a collaborator in theMicrobiome Program of the Mayo Clinic Center for Individualized Medicine.
Significance of the Findings
Roughly 20 percent of humans lack the gene that encodes proteins for processing a specific carbohydrate, a sugar in the intestinal mucus called fucose. The interaction shown by the research team is valuable because many bacteria are adept at utilizing carbohydrates such as fucose, which are abundant in the gut. Confronted with diets that have little or no complex plant sugars, these bacteria are forced to change their function, especially in hosts that lack fucose. This was seen with the altered metabolic gene expression of one of the key microbes in the gut — Bacteroides thetaiotaomicron. Changes in microbial membership or function as demonstrated in this study may, in turn, foster a "digestive landscape" that can promote inflammatory conditions such as Crohn's disease.
The microbiome represents millions of microbes in the gut and elsewhere in the body. They perform specialized functions to help keep metabolism in balance. Whether in humans or other animals, the microbial combination is unique and must function well with the individual's genome and diet for a healthy existence.
Additional researchers on the study include Angela Marcobal, Ph.D.; Samuel Smits; Erica Sonnenburg, Ph.D.; Elizabeth Costello, Ph.D.; Steven Higginbottom; Susan Holmes, Ph.D.; David Relman, M.D.; and Justin Sonnenburg, Ph.D.; all of Stanford University; Luke Ursell, University of Colorado at Boulder; Rob Knight, Ph.D., Howard Hughes Medical Institute and University of Colorado at Boulder; Steve Domino, M.D., Ph.D., University of Michigan; and Jeffrey Gordon, M.D., Washington University.
The research was supported by the National Institutes of Health, the Crohn's & Colitis Foundation of America, the Walter and Idun Berry Foundation, and the Thomas and Joan Merigan Endowment at Stanford.